Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jun 28

PMID 27347680

Citations 137

Authors

Eric Lefebvre

Graeme Moyle

Ran Reshef

Lee P Richman

Melanie Thompson

Feng Hong

Hsin-L Chou

Taishi Hashiguchi

Craig Plato

Dominic Poulin

Toni Richards

Hiroyuki Yoneyama

Helen Jenkins

Grushenka Wolfgang

Scott L Friedman

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC's anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis.

Methods: Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC's antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses.

Results: CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight.

Conclusions: CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC's antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475).

Citing Articles

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.

Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease.

Cho Y, Kwon Y, Hwang S Liver Res. 2025; 7(1):16-25.

PMID: 39959694 PMC: 11791820. DOI: 10.1016/j.livres.2022.06.001.

Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.

Biagioli M, Fiorucci S Liver Res. 2025; 5(3):119-141.

PMID: 39957845 PMC: 11791866. DOI: 10.1016/j.livres.2021.08.003.

Macrophages protect against sensory axon loss in peripheral neuropathy.

Hakim S, Jain A, Adamson S, Petrova V, Indajang J, Kim H Nature. 2025; .

PMID: 39939762 DOI: 10.1038/s41586-024-08535-1.

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E Cells. 2024; 13(19.

PMID: 39404413 PMC: 11475195. DOI: 10.3390/cells13191650.

References

Mitchell C, Couton D, Couty J, Anson M, Crain A, Bizet V . Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol. 2009; 174(5):1766-75. PMC: 2671265. DOI: 10.2353/ajpath.2009.080632. View

Friedman S, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L . Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016; 47:356-65. DOI: 10.1016/j.cct.2016.02.012. View

Ding S, Shen Z, Chen Y, Sun S, Liu Q, Xie M . Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin. 2005; 26(5):575-80. DOI: 10.1111/j.1745-7254.2005.00090.x. View

De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner D . Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology. 2007; 132(5):1937-46. DOI: 10.1053/j.gastro.2007.02.033. View

Panzer U, Steinmetz O, Stahl R, Wolf G . Kidney diseases and chemokines. Curr Drug Targets. 2006; 7(1):65-80. DOI: 10.2174/138945006775270213. View

Wree A, Broderick L, Canbay A, Hoffman H, Feldstein A . From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10(11):627-36. DOI: 10.1038/nrgastro.2013.149. View

Hashimoto E, Taniai M, Tokushige K . Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013; 28 Suppl 4:64-70. DOI: 10.1111/jgh.12271. View

Kang Y, Lee M, Song H, Ko G, Kwon O, Lim T . CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int. 2010; 78(9):883-94. DOI: 10.1038/ki.2010.263. View

Traber P, Chou H, Zomer E, Hong F, Klyosov A, Fiel M . Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013; 8(10):e75361. PMC: 3793988. DOI: 10.1371/journal.pone.0075361. View

10.

Hayashi H, Sakai T . Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol. 2011; 300(5):G729-38. PMC: 3094136. DOI: 10.1152/ajpgi.00013.2011. View

11.

Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L . Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016; 150(5):1147-1159.e5. DOI: 10.1053/j.gastro.2016.01.038. View

12.

Sheth S, Gordon F, Chopra S . Nonalcoholic steatohepatitis. Ann Intern Med. 1997; 126(2):137-45. DOI: 10.7326/0003-4819-126-2-199701150-00008. View

13.

Thompson M, Saag M, DeJesus E, Gathe J, Lalezari J, Landay A . A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 2015; 30(6):869-78. PMC: 4794136. DOI: 10.1097/QAD.0000000000000988. View

14.

Lim Y, Kim W . The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008; 12(4):733-46, vii. DOI: 10.1016/j.cld.2008.07.007. View

15.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

16.

Han J, Kim Y, Kim L, Choi S, Park I, Kim J . PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. J Korean Med Sci. 2010; 25(1):35-41. PMC: 2799997. DOI: 10.3346/jkms.2010.25.1.35. View

17.

Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K . A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013; 46(3):141-52. DOI: 10.1007/s00795-013-0016-1. View

18.

Lefebvre E, Gottwald M, Lasseter K, Chang W, Willett M, Smith P . Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. Clin Transl Sci. 2016; 9(3):139-48. PMC: 5351328. DOI: 10.1111/cts.12397. View

19.

Marra F, Tacke F . Roles for chemokines in liver disease. Gastroenterology. 2014; 147(3):577-594.e1. DOI: 10.1053/j.gastro.2014.06.043. View

20.

Reshef R, Luger S, Hexner E, Loren A, Frey N, Nasta S . Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012; 367(2):135-45. PMC: 3568501. DOI: 10.1056/NEJMoa1201248. View